China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has inked a licensing deal with TABUK Pharmaceutical Manufacturing Company, granting the Saudi Arabian company the regulatory filing and commercialization rights to two of Mabwell’s biosimilars in the Middle East and North Africa (MENA) region. The financial details of the agreement were not disclosed.
Expanding Access to High-Quality Biologics in the MENA Region
The partnership, centered around Saudi Arabia and leveraging TABUK’s extensive business network, will extend the reach of these biosimilars to multiple countries within the region, impacting nearly 500 million people. This collaboration aims to enhance the accessibility of high-quality Chinese biologics for local patients in the MENA region.
Mabwell’s Biosimilar Portfolio and Global Reach
Mabwell Bioscience boasts 9MW0311 and 9MW0321, which are biosimilars to Amgen’s Prolia and Xgeva, respectively. These products have already been licensed to the company’s partners in Brazil and Peru, demonstrating Mabwell’s commitment to expanding global access to affordable and effective biologics.-Fineline Info & Tech
